<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290574</url>
  </required_header>
  <id_info>
    <org_study_id>2014-10-019</org_study_id>
    <nct_id>NCT02290574</nct_id>
  </id_info>
  <brief_title>Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial</brief_title>
  <acronym>NEOTREAT</acronym>
  <official_title>Efficacy of Neoadjuvant Thermo-Radio-chemotherapy for Locally Advanced Rectal Cancer Before Laparoscopic Total Mesorectal Excision: Prospective Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators start this prospective study to evaluate the efficacy of laparoscopic total
      mesorectal excision after concurrent chemo-radiation therapy with hyperthermia in locally
      advanced rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard treatment of locally advanced rectal cancer is neoadjuvant concurrent
      chemo-radiation therapy (CCRT) followed by total mesorectal excision (TME). Recently,
      laparoscopic surgery is getting substitute open surgery based on the advantages of early
      recovery, short admission, less pain, less blood loss, and little scar without compromising
      oncologic outcomes.

      It is reported that hyperthermia is effective in synthetic (S) phase, Low oxgen pressure,
      acidic, and low perfusion site which are known as radio-resistant. Because of these
      characteristics, it considered as the most valuable radiosensitizer in cancer treatment,
      theoretically. Furthermore, mild hyperthermia (41 to 41.5 ÂºC) can promote tumor
      reoxygenation.

      Based on those background, the investigators start this prospective study to evaluate the
      efficacy of laparoscopic TME after CCRT with hyperthermia in locally advanced rectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Curative Resection Rate of Laparoscopic TME</measure>
    <time_frame>expected average of 6 weeks after neoadjuvant treatement</time_frame>
    <description>Curative resection rate of laparoscopic TME after CCRT and hyperthermia treament</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathologic Response of Thermo-radio-chemotherapy</measure>
    <time_frame>expected average of 6 weeks after neoadjuvant treatement</time_frame>
    <description>The pathologic response was assessed according to the Dworak's system. The pathologic response grades were as follows: grade 0, no response; grade 1, dominant tumor mass with obvious fibrosis, vasculopathy, or both (minimal response); grade 2, dominant fibrotic changes with a few easy-to-find tumor cells or groups (moderate response); grade 3, few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance (near complete response); and grade 4, no viable tumor (complete response)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event of Laparoscopic TME and Hyperthermia With CCRT</measure>
    <time_frame>expected average of 16 weeks after neoadjuvant treatement</time_frame>
    <description>Adverse event according to CTCAE V 4.0 after laparoscopic TME and hyperthermia with CCRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Open TME</measure>
    <time_frame>expected average of 6 weeks after neoadjuvant treatement</time_frame>
    <description>Rate of open TME was measured as ten percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response of Hyperthermia With CCRT</measure>
    <time_frame>expected average of 6 weeks after neoadjuvant treatement</time_frame>
    <description>Pathologic complete response of hyperthermia with CCRT was achieved in 20% of participants</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Thermo-radio-chemotherapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperthermia with concurrent chemo-radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hyperthermia with concurrent chemo-radiation therapy</intervention_name>
    <arm_group_label>Thermo-radio-chemotherapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 years or older

          -  pathologically confirmed rectal cancer

          -  Eastern Cooperative Oncology Group performance status 0 to 2

          -  Candidate of laparoscopic TME

          -  Optimal bone marrow function

          -  Locally advanced rectal cancer confirmed by magnetic resonance imaging

        Exclusion Criteria:

          -  Extrapelvic metastasis

          -  Previous pelvic irradiation

          -  Current status of pregnant or breast feeding

          -  Confirmed other malignancy within two years except thyroid cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Chul Park, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <results_first_submitted>September 4, 2018</results_first_submitted>
  <results_first_submitted_qc>October 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2019</results_first_posted>
  <last_update_submitted>October 13, 2019</last_update_submitted>
  <last_update_submitted_qc>October 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Park Hee Chul</investigator_full_name>
    <investigator_title>Assocate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Thermo-radio-chemotherapy Arm</title>
          <description>Hyperthermia with concurrent chemo-radiation therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thermo-radio-chemotherapy Arm</title>
          <description>Hyperthermia with concurrent chemo-radiation therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>age, categorical (years)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="32" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Curative Resection Rate of Laparoscopic TME</title>
        <description>Curative resection rate of laparoscopic TME after CCRT and hyperthermia treament</description>
        <time_frame>expected average of 6 weeks after neoadjuvant treatement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thermo-radio-chemotherapy Arm</title>
            <description>Hyperthermia with concurrent chemo-radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Curative Resection Rate of Laparoscopic TME</title>
          <description>Curative resection rate of laparoscopic TME after CCRT and hyperthermia treament</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Response of Thermo-radio-chemotherapy</title>
        <description>The pathologic response was assessed according to the Dworak's system. The pathologic response grades were as follows: grade 0, no response; grade 1, dominant tumor mass with obvious fibrosis, vasculopathy, or both (minimal response); grade 2, dominant fibrotic changes with a few easy-to-find tumor cells or groups (moderate response); grade 3, few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance (near complete response); and grade 4, no viable tumor (complete response)</description>
        <time_frame>expected average of 6 weeks after neoadjuvant treatement</time_frame>
        <population>40% of pathologic response rate of laparoscopic TME after CCRT and hyperthermia treament</population>
        <group_list>
          <group group_id="O1">
            <title>Thermo-radio-chemotherapy Arm</title>
            <description>Hyperthermia with concurrent chemo-radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Response of Thermo-radio-chemotherapy</title>
          <description>The pathologic response was assessed according to the Dworak's system. The pathologic response grades were as follows: grade 0, no response; grade 1, dominant tumor mass with obvious fibrosis, vasculopathy, or both (minimal response); grade 2, dominant fibrotic changes with a few easy-to-find tumor cells or groups (moderate response); grade 3, few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance (near complete response); and grade 4, no viable tumor (complete response)</description>
          <population>40% of pathologic response rate of laparoscopic TME after CCRT and hyperthermia treament</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event of Laparoscopic TME and Hyperthermia With CCRT</title>
        <description>Adverse event according to CTCAE V 4.0 after laparoscopic TME and hyperthermia with CCRT</description>
        <time_frame>expected average of 16 weeks after neoadjuvant treatement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thermo-radio-chemotherapy Arm</title>
            <description>Hyperthermia with concurrent chemo-radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event of Laparoscopic TME and Hyperthermia With CCRT</title>
          <description>Adverse event according to CTCAE V 4.0 after laparoscopic TME and hyperthermia with CCRT</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Open TME</title>
        <description>Rate of open TME was measured as ten percent</description>
        <time_frame>expected average of 6 weeks after neoadjuvant treatement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thermo-radio-chemotherapy Arm</title>
            <description>Radiation: Hyperthermia with concurrent chemo-radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Open TME</title>
          <description>Rate of open TME was measured as ten percent</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Complete Response of Hyperthermia With CCRT</title>
        <description>Pathologic complete response of hyperthermia with CCRT was achieved in 20% of participants</description>
        <time_frame>expected average of 6 weeks after neoadjuvant treatement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thermo-radio-chemotherapy Arm</title>
            <description>Hyperthermia with concurrent chemo-radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response of Hyperthermia With CCRT</title>
          <description>Pathologic complete response of hyperthermia with CCRT was achieved in 20% of participants</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>expected average of 16 weeks after neoadjuvant treatement</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Thermo-radio-chemotherapy Arm</title>
          <description>Hyperthermia with concurrent chemo-radiation therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor</name_or_title>
      <organization>Samsung Medical Center</organization>
      <phone>82-2-3410-2612</phone>
      <email>hee.ro.park@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

